These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1359653)

  • 1. Factors affecting compliance with depot injection treatment in the community.
    Tunnicliffe S; Harrison G; Standen PJ
    Soc Psychiatry Psychiatr Epidemiol; 1992 Oct; 27(5):230-3. PubMed ID: 1359653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of first episode psychotic illness in Afro-Caribbean patients.
    Chen EY; Harrison G; Standen PJ
    Br J Psychiatry; 1991 Apr; 158():517-22. PubMed ID: 1675902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional psychoses in Afro-Caribbeans.
    Harvey I; Williams M; McGuffin P; Toone BK
    Br J Psychiatry; 1990 Oct; 157():515-22. PubMed ID: 2131132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of client's ethnicity on psychotropic medication management in community mental health services.
    Ziguras S; Lambert TJ; McKenzie DP; Pennella J
    Aust N Z J Psychiatry; 1999 Dec; 33(6):882-8. PubMed ID: 10619216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical limitations of prescribing olanzapine depot (Relprevv).
    Devadason P
    Australas Psychiatry; 2010 Jun; 18(3):269. PubMed ID: 20482436
    [No Abstract]   [Full Text] [Related]  

  • 6. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.
    Valenstein M; Copeland LA; Owen R; Blow FC; Visnic S
    J Clin Psychiatry; 2001 Jul; 62(7):545-51. PubMed ID: 11488366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Depot antipsychotics in the year 2011].
    Knegtering H; Oolders H; Ruijsink MA; van der Moolen AE
    Tijdschr Psychiatr; 2011; 53(2):95-105. PubMed ID: 21319066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of schizophrenia in the Afro-Caribbean community.
    Sugarman PA
    Soc Psychiatry Psychiatr Epidemiol; 1992 Mar; 27(2):102-5. PubMed ID: 1594972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Child and adolescent psychiatric presentations of second-generation Afro-Caribbeans in Britain.
    Goodman R; Richards H
    Br J Psychiatry; 1995 Sep; 167(3):362-9. PubMed ID: 7496645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethnic differences in satisfaction with mental health services among representative people with psychosis in south London: PRiSM study 4.
    Parkman S; Davies S; Leese M; Phelan M; Thornicroft G
    Br J Psychiatry; 1997 Sep; 171():260-4. PubMed ID: 9337981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demographic factors associated with extreme non-compliance in schizophrenia.
    Sellwood W; Tarrier N
    Soc Psychiatry Psychiatr Epidemiol; 1994 Jul; 29(4):172-7. PubMed ID: 7939966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disabilities and circumstances of schizophrenic patients--a follow-up study. Ethnic aspects. A Comparison of three matched groups.
    Perera R; Owens DG; Johnstone EC
    Br J Psychiatry Suppl; 1991 Oct; (13):40-2, 44-6. PubMed ID: 1840770
    [No Abstract]   [Full Text] [Related]  

  • 13. Excessive antipsychotic dosing in 2 U.S. State hospitals.
    Diaz FJ; De Leon J
    J Clin Psychiatry; 2002 Nov; 63(11):998-1003. PubMed ID: 12444813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social aspects of therapy with depot neuroleptics in the Federal Republic of Germany.
    Haring C; Tegeler J; Lehmann E; Ptock WD
    Acta Psychiatr Belg; 1981; 81(2):189-202. PubMed ID: 6117189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia in the Afro-Caribbean community.
    Sugarman PA; Craufurd D
    Br J Psychiatry; 1994 Apr; 164(4):474-80. PubMed ID: 8038935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex, ethnicity, and antipsychotic medication use in patients with psychosis.
    Arnold LM; Strakowski SM; Schwiers ML; Amicone J; Fleck DE; Corey KB; Farrow JE
    Schizophr Res; 2004 Feb; 66(2-3):169-75. PubMed ID: 15061250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages of depot antipsychotics.
    Kennedy HG; Mikhail SW
    Lancet; 2000 Aug; 356(9229):594. PubMed ID: 10950256
    [No Abstract]   [Full Text] [Related]  

  • 18. Financial incentives to improve adherence to anti-psychotic maintenance medication in non-adherent patients - a cluster randomised controlled trial (FIAT).
    Priebe S; Burton A; Ashby D; Ashcroft R; Burns T; David A; Eldridge S; Firn M; Knapp M; McCabe R
    BMC Psychiatry; 2009 Sep; 9():61. PubMed ID: 19785727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.